Lipocine (LPCN) Status Update summary

Obesity treatment landscape and unmet needs

• Obesity is a global health crisis, with rising prevalence and 1 billion people projected to be affected by 2030, leading to significant comorbidities, morbidity, mortality, and healthcare costs.

• Current therapies like GLP-1 agonists offer significant weight loss but are associated with loss of lean mass and bone density, tolerability issues, and rapid weight regain after discontinuation.

• BMI is insufficient for assessing obesity-related health risk; more precise body composition measures are needed to guide therapy and monitor outcomes.

• There is a critical need for treatments that reduce fat while preserving or increasing muscle and bone mass.

LPCN2401 mechanism and clinical rationale

• LPCN2401 is a novel oral androgen receptor agonist (testosterone ester) designed for once-daily dosing, with a proprietary or Lip'ral-based formulation enabling effective oral absorption.

• The therapy targets fat, muscle, and bone, aiming to induce fat loss, stimulate muscle growth, and promote bone formation through mechanisms including lipolysis, reduced lipogenesis, and inhibition of adipocytokines.

• Co-formulation with vitamin E may amplify benefits by reducing oxidative stress and improving absorption.

Phase II clinical results and safety

• In a 36-week, placebo-controlled trial (n=56) in men with obesity and metabolic dysfunction, LPCN2401 (with or without vitamin E) improved body composition by reducing fat mass, increasing lean mass, and improving bone mineral content, with a 6-8% improvement in fat-to-lean ratio.

• Functional improvements included increased hand grip strength and favorable changes in walk time, especially with the vitamin E combination.

• Liver health markers improved, with reductions in ALT, AST, ALP, GGT, and liver fat, and higher rates of NASH resolution without fibrosis worsening.

• LPCN2401 was well-tolerated over 36 weeks, with adverse event rates similar to placebo and no significant androgenic or cardiovascular safety signals; open-label extension showed continued tolerability up to 72 weeks.